Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Functional evaluation of variants of unknown significance in the BRCA2 gene identified in genetic testing

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F19%3A00077984" target="_blank" >RIV/00023001:_____/19:00077984 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/00209805:_____/19:00078130

  • Výsledek na webu

    <a href="https://www.tandfonline.com/doi/abs/10.1080/15384047.2018.1550566?journalCode=kcbt20" target="_blank" >https://www.tandfonline.com/doi/abs/10.1080/15384047.2018.1550566?journalCode=kcbt20</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1080/15384047.2018.1550566" target="_blank" >10.1080/15384047.2018.1550566</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Functional evaluation of variants of unknown significance in the BRCA2 gene identified in genetic testing

  • Popis výsledku v původním jazyce

    Heterozygous germline BRCA2 mutations predispose to breast, ovarian, pancreatic and other types of cancer. The presence of a pathogenic mutation in patients or their family members warrants close surveillance or prophylactic surgery. Besides clearly pathogenic mutations, variants leading only to a single amino acid substitution are often identified. The influence of such variants on cancer risk is often unknown, making their presence a major clinical problem. When genetic methods are insufficient to classify these variants, functional assays with various cellular models are performed. We developed and applied a new syngeneic model of human cancer cells to test all variants of unknown significance in exon 18 identified by genetic testing of high-risk cancer patients in the Czech Republic, via introduction of constructs containing each of these variants into the wild-type allele of BRCA2-heterozygous DLD1 cells (BRCA2(wt/Delta ex11)). We found unaffected DNA repair function of BRCA2 in cell lines BRCA2(7997G&gt;C/Delta ex11), BRCA2(8111C&gt;T/Delta ex11), BRCA2(8149G&gt;T/Delta ex11), BRCA2(8182G&gt;A/Delta ex11), and BRCA2(8182G&gt;T/Delta ex11), whereas the cell line BRCA2(8168A&gt;G/Delta ex11) and the nonsense mutation carrying line BRCA2(8305G&gt;T/Delta ex11) did affect protein function. Targeting the BRCA2 wild-type allele with a construct carrying the variant c.7988A&gt; G resulted in incorporation exclusively into the already defective allele in all viable clones, strongly suggesting a detrimental phenotype. Our model thus offers a valuable tool for the functional evaluation of unclassified variants in the BRCA2 gene and provides a stable and distributable cellular resource for further research.

  • Název v anglickém jazyce

    Functional evaluation of variants of unknown significance in the BRCA2 gene identified in genetic testing

  • Popis výsledku anglicky

    Heterozygous germline BRCA2 mutations predispose to breast, ovarian, pancreatic and other types of cancer. The presence of a pathogenic mutation in patients or their family members warrants close surveillance or prophylactic surgery. Besides clearly pathogenic mutations, variants leading only to a single amino acid substitution are often identified. The influence of such variants on cancer risk is often unknown, making their presence a major clinical problem. When genetic methods are insufficient to classify these variants, functional assays with various cellular models are performed. We developed and applied a new syngeneic model of human cancer cells to test all variants of unknown significance in exon 18 identified by genetic testing of high-risk cancer patients in the Czech Republic, via introduction of constructs containing each of these variants into the wild-type allele of BRCA2-heterozygous DLD1 cells (BRCA2(wt/Delta ex11)). We found unaffected DNA repair function of BRCA2 in cell lines BRCA2(7997G&gt;C/Delta ex11), BRCA2(8111C&gt;T/Delta ex11), BRCA2(8149G&gt;T/Delta ex11), BRCA2(8182G&gt;A/Delta ex11), and BRCA2(8182G&gt;T/Delta ex11), whereas the cell line BRCA2(8168A&gt;G/Delta ex11) and the nonsense mutation carrying line BRCA2(8305G&gt;T/Delta ex11) did affect protein function. Targeting the BRCA2 wild-type allele with a construct carrying the variant c.7988A&gt; G resulted in incorporation exclusively into the already defective allele in all viable clones, strongly suggesting a detrimental phenotype. Our model thus offers a valuable tool for the functional evaluation of unclassified variants in the BRCA2 gene and provides a stable and distributable cellular resource for further research.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30101 - Human genetics

Návaznosti výsledku

  • Projekt

    <a href="/cs/project/NS10536" target="_blank" >NS10536: Nová metoda funkčního hodnocení variant v BRCA2 genu</a><br>

  • Návaznosti

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Ostatní

  • Rok uplatnění

    2019

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Cancer Biology and Therapy

  • ISSN

    1538-4047

  • e-ISSN

  • Svazek periodika

    20

  • Číslo periodika v rámci svazku

    5

  • Stát vydavatele periodika

    US - Spojené státy americké

  • Počet stran výsledku

    9

  • Strana od-do

    633-641

  • Kód UT WoS článku

    000465170300006

  • EID výsledku v databázi Scopus

    2-s2.0-85060025448